Company: LHI
Filing Date: 2025-05-23
Form Type: F-1
Source: 0001213900-25-046955
Chunk: 286

Company: Living Homeopathy International Ltd.
Filing Date: 2025-05-23
Form: F-1
Chunk 286
---
 into the valuation technique are observable or unobservable. The hierarchy is as follows:

| ● | Level 1 – inputs                                                                                                   
 to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. |

| ● | Level 2 – inputs                                                                                                                   
 to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for  
 identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived 
 from or corroborated by observable market data.                                                                                    |

| ● | Level 3 – inputs                               
 to the valuation methodology are unobservable. |

Unless otherwise disclosed, the fair values
of the Company’s financial instruments including cash and cash equivalents, accounts payable, accrued expenses and other payables
and amount due to a related party are approximated to their recorded values due to their short-term maturities. The carrying amount of
operating lease liabilities approximate their fair values since they bear an interest rate which approximates market interest rates.

<div align='center'>F-33</div>

The Company accounts for revenue recognition
under Accounting Standards Codification 606, Revenue from Contracts with Customers (“ASC 606”). Revenue from contracts with
customers is recognized using the following five steps:

| 1. | Identify the contract(s) 
 with a customer;         |

| 2. | Identify the performance     
 obligations in the contract; |

| 3. | Determine              
 the transaction price; |

| 4. | Allocate the transaction                                  
 price to the performance obligations in the contract; and |

| 5. | Recognize revenue when                                 
 (or as) the entity satisfies a performance obligation. |

The Company primarily generates revenue from
sales of healthcare products, personal care products and water filters and related products to individuals and distributors. The Company
recognizes revenue when payment is tendered at the point of sale as the performance obligation has been satisfied. The single performance
obligation is satisfied at a point in time when the product has been delivered to the customer and control has been passed to the customer,
no obligation is outstanding, and the Company is reasonably assured that funds have been or will be collected from the customer, i.e.,
customers settled the amount by cash or credit card. Product acceptance is evidenced by sales invoice signed by the customer upon checkout
in the Company’s office. The transaction price is determined based on a fixed consideration in the contract with customers. There
is no variable consideration, significant financing